This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Learn about ATTR-CM and uncover the differences between hereditary and wild-type ATTR-CM
Example of description text sitting alongside header
Explore a range of educational resources to support the diagnosis of ATTR-CM
Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Red Flags of ATTR-CM
Summary of Nigel Lewis' presentation at the BCS Symposium 2021 highlighting the red flags for ATTR-CM including the cardiac and non-cardiac manifestations.
Diagnosis of ATTR-CM
Summary of Kate Gatenby's presentation at the BCS Symposium 2021 highlighting the characteristic findings on imaging that would point to a diagnosis of ATTR-CM.
Management of ATTR-CM
Summary of Will Moody's presentation at the BCS Symposium 2021, discussing a case study of a patient diagnosed with ATTR-CM.
This module reviews the biological foundation and disease mechanism of ATTR amyloidosis.
This video breaks down the various types of ATTR amyloidosis and the clinical clues that can raise suspicion of ATTR-CM.
This module reviews the importance of an early diagnosis of ATTR-CM.
The last in the series video reviews non-invasive and invasive approaches for the diagnosis of ATTR-CM.
Imaging techniques for diagnosis of cardiac amyloidosis
'Ask the expert' video from the 2020 BSH Congress Symposium with Rob Cooper. Rob highlights the symptoms of cardiac amyloidosis and provides an in-depth explanation of the imaging techniques used in combination to diagnose cardiac amyloidosis accurately.
Tips for Detecting Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Summary video from the 2020 BSH Congress Symposium with Lisa Anderson, who shares some important tips for helping you to detect TTR cardiac amyloidosis, including example criteria of a patients history.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. October 2020
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021